The finalists of BiotechMed Corporate Accelerator have been selected
https://en.generation-startup.ru/media-center/news/16309/?id=56
Address:
8, Presnenskaya emb., Moscow, 123112
Search
9 November 2015

The finalists of BiotechMed Corporate Accelerator have been selected

A demo day of BiotechMed GenerationS was also held in Tomsk, where the 5 finalists of the track were determined.

The final pitch session in the framework of the I Congress "Healthcare of Russia. Advanced Development Technology” has completed its two-week training program and identified the top 5 startups of GenerationS in the field of medicine, pharmaceuticals and biotechnology, which will represent BiotechMed track at the final vote of GenerationS.

The experts of the Demo Day were the representatives of RVC, Johnson & Johnson, Martal Consulting Group, Sanofi, EFKO Group of Companies, OMB Company, KamaFlow, Severny Biopharmcluster, the innovation center of the Russian Olympic Committee, and other partner companies of GenerationS.

The highest score was given by the panel members to the following projects:

1. "Express Hemotests for key brain biomarkers for early identification of acute and chronic brain damage of ischemic and traumatic genesis" (Project leader Anzhei Zhimbiev, Ulan-Ude);

2. "GlazaMer, a device for determining the limits of stereoscopic vision" (Project leader Alexander Sevastyanov, Novosibirsk);

3. "Production of aldosterone synthase inhibitors" (project manager Andrei Gilep and Alexei Klyuchenovich, Minsk, Belarus);

4. “DAALe, Anatomic UV eye lens” (Project Manager Andrei Grishin, Nizhny Novgorod);

5. "AntionkoRAS-M, a gene therapy anticancer drug" (Project Manager Irina Alekseyenko, Moscow).

During the ceremony, the accelerator participants were awarded with special prizes from corporate partners and the partners of the track. Team of the project "Production of aldosterone synthase inhibitors" has received an invitation to the of R&D Division of Johnson&Johnson (Belgium, Berceau) to present the project to the experts of the corporation for its further development. The project in agroinnovation “Development of a biological product of complex action to protect crops and increase their yield" (Astrakhan) received a certificate confirming the industrial partnership from Sibbiofarm. A similar certificate of Farmkontrakt was given to the Laser Scalpel project (Ekaterinburg).

A certificate of CSI-Ventures venture capital fund for six month of business incubation (acceleration support by a team of business analysts, advice and assistance in building the business with the possibility to operate and use the infrastructure of biopharmaceutical building of MIPT) was given to Non-Invasive Blood Glucose Meter, a project from St. Petersburg. "Express Hemotest for key brain biomarkers" project (Ulan-Ude) received an award from Aberkeid company for the market research in the topic area of the research. Projects "The diagnostic complex for early detection of cancer” (Rosa DC) (Nizhny Novgorod) and “AntionkoRAS-M, a gene therapy anticancer drug” (Moscow) were awarded certificates from PrimerCapital venture fund. GC EFKO, a technology partner of GenerationS, provided an opportunity for 5 projects to participate in the educational program of Biryuch School of Management.

Gulnara Bikkulova, summing up the results of the track, reminded about the specifics of GenerationS 2015 and the history of the development of the accelerator: “GenerationS appeared three years ago upon the request of Russian venture capital investors who did not have enough high-quality projects in which they could invest. GenerationS is an attempt to find projects in Russian universities, technology parks and incubators, and prepare them to communicate with investors and discuss specific deals. This year GenerationS is implemented by the order of large industrial companies that determined the requirements to projects, participated in their expert evaluation and are going to work with them. The federal accelerator solves the problem of involvement of major Russian companies in working with small innovative companies, and this is a very important task to solve to develop Russia’s innovation environment.”

Olga Babkina, Deputy Vice-Rector, Research, Tomsk State University, which is the operator of BiotechMed, also spoke about the organization of this year’s accelerator: "For the second year in a row, Russian Venture Company and Tomsk State University hold BiotechMed accelerator for the projects of GenerationS. I need to say that we have introduced stricter requirements for the project: we invited to participate only those who completed the R&D or had a prototype ready, and we also made stricter requirements to the program, because the projects have already learnt the basics in marketing or business planning at their pre-accelerator program. This is why the corporate educational program of the accelerator was prepared by us in close cooperation with our corporate partners, and we consulted with them on the ways to reinforce the program, on subject areas to focus upon, on the possible “packaging” for the projects according to the requirements of corporations.”

To recall, the subject area of biotechnology and medicine was the second most popular among the participants of GenerationS 2015: 380 applications were received from 74 towns and cities. From October 26 to November 6 BiotechMed GenerationS, the corporate accelerator, featured 18 projects from Moscow, St. Petersburg, Novosibirsk, Nizhny Novgorod, Astrakhan, Ulan-Ude, Pushchino, Vladivostok, Rostov-on-Don, Yekaterinburg, Belgorod, Minsk.

BiotechMed accelerator program included participation in round tables and workshops, presentation of production and business processes in pharmaceutical and biotech companies of Tomsk and Novosibirsk, discussions with experts and individual work with mentors. Corporate partners of BiotechMed GenerationS took an active part in the work of the accelerator, including Farmcontract group of companies, Sibbiofarm Production Association and the Russian representative office of Johnson&Johnson, GC EFKO, which is the technology partner of GenS, INVITRO, Aberkeid research agency, innovation center of the Olympic Committee of Russia, Sanofi.

You have successfully subscribed!
Keep me posted!
Signing up to our project's newsletter you agree to the Terms of Use